In:
Journal of Nanoscience and Nanotechnology, American Scientific Publishers, Vol. 19, No. 11 ( 2019-11-01), p. 6866-6871
Abstract:
The main aim of present study was to enhance the anticancer effect of sorafenib (SRF) in the liver cancer cells. The SRF-loaded folate receptor-targeted polymer lipid hybrid nanoparticle was formulated to enhance the therapeutic efficacy in the treatment of liver cancers. The SRF-loaded
folic acid (FA)-conjugated lipid-coated chitosan/chondroitin sulfate (CT/CS) nanoparticle (FCCD/SRF) showed a remarkable internalization of cancer cells compared to non-targeted CCD/SRF. The higher internalization of nanoparticle was mainly attributed to the specific interaction to the folate receptors overexpressed in the liver cancer cells. FCCD/SRF exhibited a remarkable cell killing effect throughout all tested concentrations. Consistent with the cytotoxic effect, IC50 value of FCCD/SRF was 0.78 μ g/ml compared to 3.92 μ g/ml for CCD/SRF indicating the potential
of targeting strategy to the cancer cells. FCCD/SRF showed a remarkable apoptosis of cancer cells with distorted nucleus and apoptotic body formation. Overall, results showed that folate-conjugated polymer-lipid hybrid nanoparticle possess promising potential for anticancer drug delivery in the treatment of liver cancers.
Type of Medium:
Online Resource
ISSN:
1533-4880
DOI:
10.1166/jnn.2019.16936
Language:
English
Publisher:
American Scientific Publishers
Publication Date:
2019
SSG:
11
Permalink